Semaglutide and Cardiovascular Risk: What the SELECT Study Showed in 2026

For years, the medical community knew that semaglutide helped patients with type 2 diabetes lose weight and control blood sugar. What nobody expected was that the medication would have a profound effect on the hearts of people who did not even have diabetes. The SELECT study changed that narrative completely.

What Was SELECT and Who Participated

SELECT was a large-scale clinical trial that followed more than 17,000 adults over five years. All participants had obesity or overweight, but none had diabetes. The central question was straightforward: did semaglutide reduce the risk of cardiac events in this population?

The answer was clear. Patients who received weekly semaglutide had 20 percent fewer major cardiovascular events, such as heart attacks, strokes, and death from cardiac causes, compared with those who took a placebo. That number carries a lot of weight. Out of every five events expected in the untreated group, one was prevented. In practical terms, that can be the difference between life and death for thousands of people.

Why This Result Was So Unexpected

Until SELECT, the cardiac benefits of GLP-1 agonists had been observed mainly in people with diabetes. Diabetes is an enormous cardiovascular risk factor, so finding a benefit there was not a surprise. But in people without blood sugar issues, the picture changed completely.

It was not just about losing kilos. The risk reduction appeared independently of how much weight each person lost. This suggests that the medication acts on multiple pathways at the same time: it reduces inflammation, improves endothelial function, which is the inner layer of blood vessels, lowers blood pressure, and modifies cholesterol levels. It is an effect that goes well beyond the number on the scale.

What This Means in Practice

If you have obesity and are evaluating treatment options, this data is relevant to you. It is not about taking a medication and considering the matter resolved. It is about an approach that, within a broader plan, can offer advantages that go beyond the number on the scale.

The medication does not work in isolation. Nutrition, movement, and regular medical follow-up remain fundamental pillars. In that sense, having a tool that helps you log your routine and maintain consistent habits makes a difference. Ozempro lets you manage that tracking in a practical way, without unnecessary complications. If you want to know whether this approach makes sense for your particular situation, you can access this quiz by clicking here to get guidance on the first steps.

What Is Still Not Fully Understood

The study had important limitations. It did not include people with a body mass index below 27, nor did it follow participants beyond five years. It also does not clarify what happens if someone stops treatment after that period. Individual response varies greatly. What works for one person may not be the best option for another, and that remains a conversation that needs to happen with a healthcare professional.

Another issue is cost. In many health systems, covering semaglutide for people without diabetes remains a challenge. Although it is still not universally covered, many insurers are reviewing their policies precisely because of these results.

Should You Talk to Your Doctor?

If you have obesity, even without diabetes, and are concerned about cardiac risks, it is worth consulting. Only a healthcare professional can assess your particular situation, consider your history, and tell you whether semaglutide makes sense for you. This is not about rushing toward the first solution that appears or self-medicating. It is about making an informed decision, with professional support, understanding what each option implies in practice.

Ozempro can help you better organize your routine while you evaluate options together with your medical team. The app lets you log habits, track changes, and maintain a more structured routine, which makes the conversation with your doctor at each appointment easier and makes the whole process less overwhelming.

In Summary

The SELECT study demonstrated that semaglutide significantly reduces cardiovascular risk in people with obesity without diabetes. It is an important result that expands the profile of this medication. But it remains one tool within a broader approach that includes healthy lifestyle habits and consistent professional follow-up. Talk to your doctor about your specific circumstances. Every body is different, and the best decision is always the one made with information and support.